News in Brief
Health - Today
Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research
Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research
Pharmacology - Oct 22
Roche's VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq (atezolizumab)
Roche's VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq (atezolizumab)
News in Brief
Health - Today
Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research
Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research
Pharmacology - Oct 22
Roche's VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq (atezolizumab)
Roche's VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq (atezolizumab)